Michael D. Taylor

Queen Mary University of London — United Kingdom

Medicine · Health Sciences

131h-index75.6kcitations1.7kworks2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(742), Hedgehog Signaling Pathway Studies(263), Epigenetics and DNA Methylation(206), Chromatin Remodeling and Cancer(156), Cancer Genomics and Diagnostics(125)

Publications1.7k total

Table S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Table S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Supplemental Figure S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Supplemental Figure S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Supplemental Figure S7 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Supplemental Figure S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Supplemental Figure S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Table S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Table S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Supplemental Figure S6 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Supplemental Figure S5 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
2025Open Access
Targeting TET3 suppresses group 3 medulloblastoma stemness and progression via impairing hypomethylation of Otx2 super-enhancer
Cell Reports Medicine·2025Open Access
Supplementary Table S2 from Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
2025Open Access
Supplementary Data from Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
2025Open Access
Supplementary Table S4 from Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
2025Open Access
Supplementary Table S1 from Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
2025Open Access
Supplementary Data from Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
2025Open Access
Supplementary Table S3 from Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
2025Open Access
Supplementary Table S5 from Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
2025Open Access
Supplementary Data from Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
2025Open Access
page 1 of 83Next →

Frequent Co-authors

Paul A. Northcott(28), Stefan M. Pfister(26), Andrey Korshunov(23), Marcel Kool(21), David Jones(20), Marc Remke(17), Peter Lichter(17), Vijay Ramaswamy(17), Nada Jabado(16), Scott L. Pomeroy(15), Éric Bouffet(15), Jan Köster(14), Cynthia Hawkins(14), Amar Gajjar(13), Marina Ryzhova(13), Olaf Witt(13), Uri Tabori(13), Roland Eils(13), Richard J. Gilbertson(12), Andreas von Deimling(12)